"Designing Growth Strategies is in our DNA"
The global autoinjectors market size was USD 111.16 billion in 2023, and is projected to grow from USD 121.33 billion in 2024 to USD 307.26 billion by 2032, exhibiting a CAGR of 12.3% during the forecast period (2022-2032). North America dominated the global market with a share of 59.2% in 2023.
Autoinjectors are spring-loaded devices with a pre-filled syringe to self-administer a fixed dose of parental medicines in a patient. These devices treat selected chronic diseases, such as rheumatoid arthritis multiple sclerosis, and emergency treatments, including anaphylactic shock and migraine attacks. The incidence rate of emergency conditions, such as anaphylactic shock and migraine attacks, is increasing due to several causative agents, such as food allergens, insect bites, or drug insensitivity, across the globe. Owing to the rising incidence, the demand for biological therapies for treating these chronic diseases is high.
Thus, pharma companies are now introducing self-administration therapies to ensure patient dose compliance and easy route of administration. Several self-injection devices, such as jet injectors, pens, autoinjectors, and pre-filled syringes, are being developed by leading players for delivering medications, such as injectable vaccines and chronic disease medications.
The adoption of these devices for emergency and chronic disease therapy among the population is increasing owing to potential advantages such as easy administration and high accuracy & compliance. Thus, the rising prevalence of chronic diseases across the globe and the increasing adoption of self-injection devices among patients are expected to augment market growth over the forecast period.
The COVID-19 pandemic decreased the growth of the global market in 2020. Several regions witnessed restrictions in accessing medical care and treatments due to lockdowns. These factors also affected the number of patient visits to hospitals and healthcare centers, which further limited the disease diagnosis rate and treatments. International supply chain disruptions amid the pandemic led to shortages of critical medical devices.
However, the resurgence of routine healthcare services after the initial COVID-19 shutdown and patient visits to healthcare centers increased globally. Moreover, rising patient preference for self-administration of drugs at homecare settings propelled the market growth. Also, the rising production of high-efficacy devices by market players and their growing sales across developing countries further boosted the market share.
Thus, the rebound in diagnosis and treatment of chronic diseases post-pandemic, coupled with the high adoption of these devices in home settings, boosted the global autoinjectors market growth.
Broad Adoption of Disposable Autoinjectors among Patients to Boost Market Growth
Healthcare professionals have utilized injection systems as convenient drug delivery devices for treating patients by subcutaneous injections. However, challenges associated with conventional injection devices, such as needle stick injury, multiple low-dose injections, and high costs associated with recurrent hospital visits, limited their preference among patients.
Thus, several market players are focused on developing and launching self-injection and wearable devices with high efficacy, patient compliance, and low cost globally. These products comprise accurate dosage volumes and already reconstituted drugs, with minimized chances of needle stick injuries. Thus, such potential advantages of autoinjectors over other conventional devices drive patient adoption and adherence to these devices.
Moreover, the number of prescriptions by healthcare professionals for self-injection devices at acute care centers increased awareness among patients suffering from chronic diseases. This led to increased awareness of drug delivery systems and a high preference for self-injection devices at home among patients. Moreover, the extensive presence of more user-friendly, efficient, and patient-compliant products by injectable device industry players augmented the adoption of these devices.
In addition, supportive regulatory authorities leading to several industry players receiving regulatory approvals for disposable autoinjectors for the treatment of various types of medical conditions.
Request a Free sample to learn more about this report.
Technological Advancements in Device Platforms to Offer Lucrative Opportunities
The demand for autoinjectors is rising across the globe owing to increasing incidence rates of chronic diseases such as diabetes and rheumatoid arthritis. Thus, owing to the high incidence, several market players are shifting their focus toward the development of platform device technologies to support faster development and lessen device costs. Moreover, the rising focus of key players to enable high-volume delivery of a range of biosimilars and biologics for patients in home settings will drive market growth.
Moreover, the production and introduction of reusable technologically advanced platforms supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry are increasing. Similarly, key players are now emphasizing adding new devices to their existing product portfolio to enable self-administration by patients for larger-volume medications. The increasing launches of autoinjectors with a wide range of applications across different medical conditions, such as cancers and autoimmune disorders, will further propel the presence of these devices across developed nations, further boosting market growth.
Therefore, the rising production of self-injection devices by key players is boosting the introduction of advanced devices across the globe, further propelling market growth.
Limited Availability of Adrenaline Autoinjectors across Developing Countries to Hamper Market
Adrenaline (epinephrine) is the first-line treatment for anaphylaxis by healthcare professionals. However, despite its pivotal role, the autoinjectable formulation is not readily available in most countries, thus preventing optimal management of patients with anaphylaxis. Similarly, the lack of availability of this emergency medication for immediate injection in an anaphylactic reaction increases the risk of progression to a severe episode and death.
Moreover, these devices lack extensive availability through official distribution networks, such as retail or drugstore pharmacies across the globe. Similarly, these devices are only obtained through special licensing arrangements and distribution on a named-patient basis across several developing countries.
Thus, scarcity of epinephrine injection devices across distribution channels at retail pharmacies, leading to less adoption of autoinjectors among patients, may hamper the market growth.
High Emphasis of Key Players on Device Launches to Cater to Disposable Segment Growth
By type, the market is segmented into disposable and reusable. The disposable segment accounted for the largest share in 2023. This growth was attributed to the rising prevalence of chronic diseases across the globe, the rising recommendation of disposable devices by healthcare professionals, and the high preference for single-use devices by patients.
In addition, industry players' rising focus on launching innovative disposable devices and rising product approval by regulatory agencies further propelled the segment share.
Whereas, the reusable segment to register a comparatively higher CAGR over the projected period. The segment growth is driven by high potential advantages over disposable devices, such as ease of use, cost-effectiveness, and high safety. Moreover, rising emphasis by several key players on the introduction of devices to facilitate the growing market for subcutaneous injections used to treat chronic diseases such as rheumatoid arthritis, Crohn’s’ disease, and multiple sclerosis is primarily contributing to the segment growth.
Several market players are focusing on the development of reusable auto-injectors as a low-waste alternative.
To know how our report can help streamline your business, Speak to Analyst
Increasing Demand for Insulin Injectable Led to Diabetes Segment Growth
Based on application, the market is segmented into autoimmune disorders, diabetes, emergency care, and others.
By application, the diabetes segment accounted for the highest autoinjectors market share in 2023, owing to the increasing demand for injectable insulin among the rising diabetes population and initiatives by leading players to develop novel products to cater the demand for diabetes management among patients.
On the other hand, the emergency care segment is projected to register a significant CAGR during the forecast period. The growth is attributable to a high incidence rate of anaphylactic episodes among the population due to specific causative agents such as food allergens, insect bites, and drug hypersensitivity and rising demand for self-injection devices for the treatment of anaphylaxis.
Furthermore, some of the government authorities are funding autoinjectors for emergency treatment of anaphylaxis.
High Potential Advantages of Intramuscular Administration to Boost the Adoption
On the basis of the route of administration, the global market is segmented into intramuscular and subcutaneous.
The intramuscular segment held a higher share of the market in 2023. The dominant share was due to the high potential advantages of intramuscular products, such as rapid onset of action, convenience, and minimal pain among patients. Similarly, the high adoption of intramuscular injections among healthcare professionals for pediatric patients further boosts the segment share in the global market.
On the contrary, the subcutaneous segment to register relatively higher CAGR during 2024-2032, owing to increasing demand for self-administration devices among home-use patients. Similarly, the rising production of subcutaneous devices by key players and increasing regulatory approvals of autoinjectors owing to high demand further propels the segment growth.
Rising Hospital Visits for Chronic Disorders to Boost Uptake of Autoinjectors
Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the highest market share in 2023. The highest share was attributed to the rising prevalence of chronic diseases, such as diabetes and rheumatoid arthritis among the geriatric population and increasing hospital visits to diagnose and treat these chronic diseases across the globe. Moreover, rising emergency cases in hospital settings owing to several factors, such as hospital-acquired infections and drug-induced anaphylaxis, among others, also boosted the use of these devices, further propelling the segment growth.
Retail pharmacies are expected to grow at a significant CAGR during the forecast period. The growth is attributable to key players' rising focus on enhancing sales and distribution networks of these devices across developing countries.
Rising Autoinjector Prescriptions by Healthcare Professionals to Propel Market Growth in North America
Based on region, the market can be divided into Europe, Latin America, North America, Asia Pacific, and the Middle East & Africa.
North America Autoinjectors Market Size, 2023 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
The North American market was valued at USD 65.81 billion in 2023, and is expected to lead the global market in the forthcoming years. An increase in R&D and the introduction of new technologies in self-injection devices by the key players to support in-patient treatment likely to drive the market growth in North America. Moreover, healthcare professionals' rising emphasis and recommendation of autoinjector prescriptions against anaphylactic episodes will further boost the regional share.
Europe is the second most dominated region in terms of revenue and market share in 2023. The market in Europe held a significant share due to increasing collaborations among manufacturing players to boost production, and rising approvals of new injectable devices across the region further boosted the European market.
In Asia Pacific, the market growth is driven by the growing prevalence of chronic disorders amongst the population. Huge demand for emergency care at home settings among patients is anticipated for the region's growth at the highest CAGR.
Conversely, the Latin American market is likely to grow slower. The region's growth is due to rising chronic disease prevalence amongst the population and the high adoption of these devices by patients in homecare settings. The market in the Middle East & Africa region is projected to grow at a moderate CAGR during the forecast period owing to the rising diagnosis and treatment rate of anaphylaxis, creating demand for these devices.
Leading Companies Focus on Adoption of Various Organic and Inorganic Growth Strategies to Maintain Their Positions
The global market is majorly led by producers such as Viatris, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., and other prominent players. Prominent market participants are concentrating on increasing investments in device production centers and rising collaborations & acquisitions owing to the huge demand for these devices globally. These factors are expected to boost the market growth.
Similarly, other major market players, including Recipharm AB, ALK-Abelló A/S, and Phillips-Medisize, are constantly focused on inorganic developments, such as enhancing their distribution channel across the global market through strategic partnerships and extensive product approvals across the globe. Such initiatives by key players are projected to propel the global market and register growth by 2032.
Thus, such continuous engagements in the production of devices by several market players and a rising focus on enhancing their distribution channels across the global market through inorganic strategies to establish their footprints in emerging nations are expected to propel market expansion over the forecast period.
An Infographic Representation of Autoinjectors Market
To get information on various segments, share your queries with us
The global market report provides detailed market analysis and focuses on crucial aspects such as leading players, product types, and major applications of the product. Additionally, it offers insights into market trends, and key industry developments such as mergers, partnerships, & acquisitions. In addition to the factors mentioned above, the report includes the factors that have contributed to the market's growth in recent years with a regional analysis of different segments.
To gain extensive insights into the market, Request for Customization
ATTRIBUTE | DETAILS |
Study Period | 2019-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2019-2022 |
Growth Rate | CAGR of 12.3% over 2024 to 2032 |
Unit | Value (USD billion) |
Growth Rate | CAGR of 12.3% from 2024-2032 |
Segmentation | By Type
|
By Application
| |
By Route of Administration
| |
By Distribution Channel
| |
By Geography
|
Fortune Business Insights says that the global market size was USD 111.16 billion in 2023 and is projected to reach USD 307.26 billion by 2032.
Registering a CAGR of 12.3%, the market will exhibit steady growth over the forecast period (2024-2032).
By type, the disposable segment is expected to lead this market in 2023.
The rising prevalence of chronic diseases and the increasing launch of advanced products across the globe are the key factors driving the market growth.
Viatris, Teva Pharmaceuticals Inc., and AstraZeneca are major companies in the global market.
The growing prevalence of chronic disorders and the surge in the adoption of these devices in home settings across the globe are expected to drive the adoption of these devices.
US +1 833 909 2966 ( Toll Free )